HIV treatment study for injectable cabotegravir/rilpivirine in Belgium
Part of Immune system & allergy, Infections clinical trials.
This study looks at people in Belgium who have already received at least one dose of a long-acting injectable HIV medication called cabotegravir/rilpivirine. The goal is to learn more about how this treatment works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have HIV-1 (the most common type of HIV).
- You must have received at least one injection of cabotegravir/rilpivirine between September 1, 2021, and March 31, 2024.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
This study follows people with HIV who are starting or have recently started a treatment using two long-acting medications, cabotegravir and lenacapavir. It aims to see how well this combination works in real life, which could help improve care for others.
This study looks at how people living with HIV feel about switching to a new injectable treatment called cabotegravir and rilpivirine. It aims to understand real-life experiences and quality of life after making the switch.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.